Thursday August 12, 2021 Daily news on ASX-listed biotechnology companies
* AS X FLAT, BIOTECH DOWN: PROTEOMICS UP 11%; ANTISENSE DOWN 10% * PHARMAXIS REVENUE UP 207% TO $22.7m, LOSS DOWN 79% TO $3m * ANTISENSE: FDA WANTS MORE DATA FOR ATL1102 DMD APPLICATION
* PROTEOMICS HIRES BIOTEM FOR PROMARKERD KIDNEY DISEASE KITS * IMAGION, OCT WORK ON NANO-SCINTILLATOR FOR BREAST CANCER * AUSTRALIA ALLOWS EYE CO PATENT FOR GEOGRAPHIC ATROPHY * VGI: INFORMED SPORT CERTIFIES NE1-ELITE ‘NO BANNED SUBSTANCES’ * DIMERIX REQUESTS ‘CAPITAL RAISING’ TRADING HALT * CRESO REQUESTS ‘CANADA HEALTH LICENCE’ TRADING HALT * FACTOR TO HOLD 10-TO-11 CONSOLIDATION * JASON CARROLL TAKES 5% OF ISLAND * OSPREY APPOINTS MARTIN EMERSON DIRECTOR
Imagion Biosystems says it has a joint development agreement with Global Cancer Technology (GCT) to develop nano-scintillator technology for breast cancer.
Imagion says that the San Diego, California-based Global Cancer Technology licensed the nano-scintillator technology from the University of California San Diego.
The company said the technology was also known as scintillating nanocrystals, which emit photons when activated by low dose gamma radiation, and enabled a controlled release of a therapeutic agent, with the approach, known as x-ray-induced photodynamic therapy, had the potential to deliver a more localized and effective dose of drug to treat cancers. The company said it had been working with Global Cancer Technology over the past year and that the joint work on its nano-scintillators would support the company as it developed its Magsense cancer imaging technology.
Imagion said it would be paid for certain research and development services and gain an ownership interest in the arising nano-scintillator product.
Imagion executive chair Bob Proulx said that the project was ‘value adding to our mission of developing nano-particle-based imaging agents and therapies”.
“As we continue to develop the Magsense imaging technology, the nano-scintillators provide Imagion with a foothold to a unique high-value therapeutic product: he said. Imagion was up 0.3 cents or 3.85 percent to 8.1 cents with 14.6 million shares traded.